Stocks · News reference
NeuroOne Completes Three Large-Animal StereoCED Procedures, Including Combined Drug Delivery And Brain Recording; Builds Momentum Toward Planned Launch Of The StereoCED Platform For Human Investigational Clinical Studies Later This Quarter
Successful Large-Animal Procedures Build Momentum Toward Planned Launch of the StereoCED™ Platform for Human Investigational Clinical Studies Later This Quarter Related StereoCED™ Revenue Expected to be Recognized in
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 27, 2026, 1:08 PM
- Checked
- Aug 27, 2026, 1:08 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
NeuroOne Medical Technologies shares are trading higher after the company announced it has completed three separate large-animal procedures using its next-generation StereoCED platform.
Read original at benzinga8-K filing — NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)
Filed: 2026-08-27 AccNo: 0001213900-26-094174 Size: 228 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgar